State-Of-The-Art Human Gene Therapy: Part II. Gene Therapy Strategies and Clinical Applications

被引:0
|
作者
Wang, Dan [1 ]
Gao, Guangping [1 ,2 ,3 ]
机构
[1] Univ Massachusetts, Sch Med, Gene Therapy Ctr, Worcester, MA 01605 USA
[2] Univ Massachusetts, Sch Med, Dept Microbiol & Physiol Syst, Worcester, MA 01605 USA
[3] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu 610064, Sichuan, Peoples R China
基金
美国国家卫生研究院;
关键词
LEBER CONGENITAL AMAUROSIS; ENGINEERED NUCLEASES; IMMUNE-RESPONSES; RPE65; MUTATIONS; VECTORS; PROGRESS; AUGMENTATION; CONSTRUCTS; PROTECTION; INFECTION;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
In Part I of this Review (Wang and Gao, 2014), we introduced recent advances in gene delivery technologies and explained how they have powered some of the current human gene therapy applications. In Part II, we expand the discussion on gene therapy applications, focusing on some of the most exciting clinical uses. To help readers to grasp the essence and to better organize the diverse applications, we categorize them under four gene therapy strategies: (1) gene replacement therapy for monogenic diseases, (2) gene addition for complex disorders and infectious diseases, (3) gene expression alteration targeting RNA, and (4) gene editing to introduce targeted changes in host genome. Human gene therapy started with the simple idea that replacing a faulty gene with a functional copy can cure a disease. It has been a long and bumpy road to finally translate this seemingly straightforward concept into reality. As many disease mechanisms unraveled, gene therapists have employed a gene addition strategy backed by a deep knowledge of what goes wrong in diseases and how to harness host cellular machinery to battle against diseases. Breakthroughs in other biotechnologies, such as RNA interference and genome editing by chimeric nucleases, have the potential to be integrated into gene therapy. Although clinical trials utilizing these new technologies are currently sparse, these innovations are expected to greatly broaden the scope of gene therapy in the near future.
引用
收藏
页码:151 / 161
页数:11
相关论文
共 50 条
  • [1] State-Of-The-Art Human Gene Therapy: Part I. Gene Delivery Technologies
    Wang, Dan
    Gao, Guangping
    DISCOVERY MEDICINE, 2014, 18 (97) : 67 - 77
  • [2] State-of-the-art gene therapy in epilepsy
    Walker, Matthew C.
    CURRENT OPINION IN NEUROLOGY, 2025, 38 (02) : 128 - 134
  • [3] Special Issue Features State-of-the-Art in Clinical Gene Therapy
    Herzog, Roland W.
    Frederickson, Robert M.
    MOLECULAR THERAPY, 2020, 28 (09) : 1933 - 1933
  • [4] State-of-the-Art 2019 on Gene Therapy for Phenylketonuria
    Grisch-Chan, Hiu Man
    Schwank, Gerald
    Harding, Cary O.
    Thoeny, Beat
    HUMAN GENE THERAPY, 2019, 30 (10) : 1274 - 1283
  • [5] State-of-the-art 2023 on gene therapy for phenylketonuria
    Martinez, Michael
    Harding, Cary O.
    Schwank, Gerald
    Thony, Beat
    JOURNAL OF INHERITED METABOLIC DISEASE, 2024, 47 (01) : 80 - 92
  • [6] State-of-the-art 2003 on PKU gene therapy
    Ding, ZB
    Harding, CO
    Thöny, B
    MOLECULAR GENETICS AND METABOLISM, 2004, 81 (01) : 3 - 8
  • [7] Regulatory and Scientific Advancements in Gene Therapy: State-of-the-Art of Clinical Applications and of the Supporting European Regulatory Framework
    Carvalho, Marta
    Sepodes, Bruno
    Martins, Ana Paula
    FRONTIERS IN MEDICINE, 2017, 4
  • [8] Gene Therapy in Liver Diseases: State-of-the-Art and Future Perspectives
    Domvri, Kalliopi
    Zarogoulidis, Paul
    Porpodis, Konstantinos
    Koffa, Maria
    Lambropoulou, Maria
    Kakolyris, Stylianos
    Kolios, George
    Zarogoulidis, Konstantinos
    Chatzaki, Ekaterini
    CURRENT GENE THERAPY, 2012, 12 (06) : 463 - 483
  • [9] Gene therapy: The first two decades and the current state-of-the-art
    Flotte, Terence R.
    JOURNAL OF CELLULAR PHYSIOLOGY, 2007, 213 (02) : 301 - 305
  • [10] THE STATE-OF-THE-ART OF CLINICAL GENE DIAGNOSIS
    GILLESPIE, DH
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 1987, 1 (01) : 42 - 51